Navigation Links
China-Biotics, Inc. Appoints New Vice President
Date:10/30/2009

SHANGHAI, Oct. 30 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced the appointment of Dr. Tom Gu as Vice President, effective November 2. In this role, Dr. Gu will oversee the development of China Biotics' probiotics products in order to meet the growing demand the Company has seen from China and the global market.

Dr. Gu has an impressive background in biochemistry and pathology with extensive practical experience in U.S. FDA-certified medical applications obtained from his work at China-based medical companies over the past eight years. Previously, Dr. Gu served as project manager for Life Technologies Corporation in the United States. Dr. Gu graduated from the University of Arizona with a Ph.D in molecular medicine. He received an EMBA from North Virginia University and a Bachelor of Science degree in biochemistry from Jilin University of China. Dr. Gu has also conducted postdoctoral research with the National Institutes of Health and previously served as a director of the United States Federation for Culture Collections. In addition, Dr. Gu is currently a member of the Expert Committee of the Shanghai Zhangjiang Bio-Pharmaceutical Base.

"We are very excited to have someone of Dr. Gu's caliber join us and lead our research and development team," said Mr. Jinan Song, Chairman and Chief Executive Officer of China Biotics. "His impressive academic achievements and practical experience will enhance and solidify our R&D capabilities, which will be of critical importance as we expand the scale of our operations. We are currently in trial production at our new 150 metric ton probiotics facility, which we expect to complete by year end. At that point, we will begin the second phase of our capacity expansion. Dr. Gu's education and practical experience in United States will be an asset in evaluating and assessing potential overseas business opportunities."

"I'm delighted to have the opportunity to join a company with such a strong reputation for innovation and quality as China-Biotics. I look forward to sharing my knowledge and experience in order to help China-Biotics further extend its reach and reputation as a leading probiotics company," said Dr. Gu.

About China-Biotics, Inc.

China-Biotics, Inc., a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

     Eva Yan, CFO
     Email: evayan@chn-biotics.com
     Web:   http://www.chn-biotics.com

     CCG Investor Relations
     Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE China-Biotics, Inc.


'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit
2. China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results
3. China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
4. China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations
5. China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results
6. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
7. China-Biotics, Inc. to Join Russell 3000 Index
8. China-Biotics, Inc. to Attend Digestive Disease Week 2009
9. China-Biotics, Inc. to Present at CCG Investor Relations China Rising Conference
10. China-Biotics, Inc. Supplies Probiotics as Additive for Poultry Feed
11. China-Biotics, Inc. Appoints New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):